Pacific Biosciences Of California (PACB) Restructuring Costs (2021 - 2023)
Pacific Biosciences Of California's quarterly Restructuring Costs came in at $63000.0 in Q4 2023, down 99.3% quarter-over-quarter from $9.0 million in Q3 2023.
Pacific Biosciences Of California has reported Restructuring Costs for 2 years, with the latest figure at $63000.0 in Q4 2023.
- For the quarter ending Q4 2023, Restructuring Costs changed N/A year-over-year to $63000.0; the trailing twelve-month figure through Dec 2024 stood at $9.0 million (changed N/A YoY), and the FY2023 full-year result was $9.0 million, changed N/A from the prior year.
- Restructuring Costs for Q4 2023 stood at $63000.0, down from $9.0 million in the prior quarter.
- The five-year high for Restructuring Costs was $12.0 million in Q3 2021, with the low at $63000.0 in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Pacific Biosciences Of California | 481.66 Mn | 205.70 Mn | 12.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 63,000.00 |
| Sep 30, 2023 | 8.98 Mn |
| Dec 31, 2021 | 403,000.00 |
| Sep 20, 2021 | 12.00 Mn |